Zoetis Q2 2026 revenue flat organically as U.S. companion-animal weakness persists, offset by livestock and international; EPS edges up on buybacks

What happened

Zoetis reported Q2 2026 revenue of $2.5 billion, flat on a reported basis and down 1% organically, as continued pressure in U.S. companion-animal categories—particularly the OA monoclonal antibody franchise—was partially offset by growth in livestock, diagnostics, and international markets. Adjusted net income fell 2% organically, but adjusted diluted EPS rose 4% to $1.87, benefiting from a lower share count following share repurchases, highlighting the company's use of buybacks to protect per-share earnings amid top-line stagnation. The organic revenue decline marks a deterioration from the low-single-digit growth seen in prior quarters and falls short of the 5.5–6.5% organic growth target embedded in management’s earlier guidance, signaling that the recovery in companion-animal demand is taking longer than expected. While Livestock, diagnostics, and international segments provided some counterbalance, the core U.S. companion business—driven by dermatology, parasiticides, and OA therapies—remains under pressure from safety concerns, competitive launches, and a more cautious veterinary spending environment. The results reinforce the narrative that Zoetis’s growth engine has downshifted, with margin resilience from share buybacks only partially offsetting sluggish revenue, which is likely to keep the stock in a holding pattern until there are clearer signs of reacceleration.

Implication

Investors should brace for continued low growth as U.S. companion-animal headwinds, especially around Librela, show no sign of abating, and the OA franchise may take years to stabilize, not quarters. EPS growth generated solely through buybacks is a weak foundation for long-term total return, particularly if revenue continues to shrink organically, eroding the quality of earnings. At current valuations, even a modest P/E of ~21x is hard to justify when organic growth is negative, increasing the risk of multiple compression toward the high teens or lower, consistent with a bear-case scenario. The offset from livestock and diagnostics is positive but insufficient to restore confidence, and the company remains highly reliant on a handful of blockbuster brands that face increasing competition. Without a concrete catalyst—such as positive Phase IV Librela data, a significant new product launch, or a broader acceleration in companion-animal spending—the stock is likely to remain range-bound with a downward bias, warranting a cautious wait-and-see approach and a lower entry target.

Thesis delta

The DeepValue report’s base-case assumption of ~6% organic revenue growth has been clearly broken, with Q2 2026 organic revenue declining 1%, pushing the stock closer to the bear case. This sustained stagnation suggests the OA mAb recovery and overall companion-animal momentum are weaker than previously modeled, reducing the probability of a near-term re-rating and increasing downside risk. The thesis now tilts more bearish, and the prior WAIT rating remains appropriate only at a much lower valuation.